Trial · NCT00570089
Microvascular Coronary Disease In Women: Impact Of Ranolazine
NCT00570089, Phase 2, Completed, Cedars-Sinai Medical Center; results first posted 2015-12-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Microvascular Coronary Disease In Women: Impact Of Ranolazine. Trials, record NCT00570089. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00570089
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Microvascular Coronary Disease In Women: Impact Of Ranolazine
- NCT number
- NCT00570089
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- Cedars-Sinai Medical Center
- Conditions
- Myocardial Ischemia
- Interventions
- Ranolazine, Placebo
- First posted
- 2007-12-10
- Last updated
- 2019-06-10
- Results first posted
- 2015-12-03
- Limitations and caveats
- This was a pilot study.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cardiac Magnetic Resonance (CMRs) | 4 weeks and 10 weeks | Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 4th week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion defect in percentage. |
| Secondary | Seattle Angina Questionnaire (SAQ) | 4 weeks and 10 weeks | Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period. The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important. Each final SAQ domain ranges from 0-100, where higher is a better outcome score. Subscales are not combined. Median, SD and range are calculated for each domain. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cardiac Magnetic Resonance (CMRs) | 4 weeks and 10 weeks | Percentage of ischemic myocardium | MEDIAN | |
| SECONDARY | Seattle Angina Questionnaire (SAQ) | 4 weeks and 10 weeks | units on a scale | MEDIAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cardiac Magnetic Resonance (CMRs) | Study Drug Ranexa - CMRs (10 CMR 1 and 10 CMR 2) | 11.7 | Full Range 8.0 to 19.3 | Percentage of ischemic myocardium | |
| Cardiac Magnetic Resonance (CMRs) | Placebo - CMRs (10 CMR 1 and 10 CMR 2) | 16.0 | Full Range 8.6 to 22.7 | Percentage of ischemic myocardium | |
| Seattle Angina Questionnaire (SAQ) | Study Drug | Physical Functioning | 91.7 | Full Range 79.2 to 97.9 | units on a scale |
| Seattle Angina Questionnaire (SAQ) | Placebo | Physical Functioning | 83.3 | Full Range 66.6 to 97.2 | units on a scale |
| Seattle Angina Questionnaire (SAQ) | Study Drug | Angina Stability | 75 | Full Range 50 to 100 | units on a scale |
| Seattle Angina Questionnaire (SAQ) | Placebo | Angina Stability | 50 | Full Range 25 to 75 | units on a scale |
| Seattle Angina Questionnaire (SAQ) | Study Drug | Angina Frequency | 80 | Full Range 50 to 100 | units on a scale |
| Seattle Angina Questionnaire (SAQ) | Placebo | Angina Frequency | 75 | Full Range 60 to 87.5 | units on a scale |
| Seattle Angina Questionnaire (SAQ) | Study Drug | Treatment Satisfaction | 87.5 | Full Range 75 to 100 | units on a scale |
| Seattle Angina Questionnaire (SAQ) | Placebo | Treatment Satisfaction | 93.8 | Full Range 75 to 100 | units on a scale |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 | STARTED | Study Drug Ranexa Then Placebo | 10 | |
| Period 1 | STARTED | Placebo Then Study Drug Ranexa | 10 | |
| Period 1 | COMPLETED | Study Drug Ranexa Then Placebo | 10 | |
| Period 1 | COMPLETED | Placebo Then Study Drug Ranexa | 10 | |
| Period 1 | NOT COMPLETED | Study Drug Ranexa Then Placebo | 0 | |
| Period 1 | NOT COMPLETED | Placebo Then Study Drug Ranexa | 0 | |
| Perod 2 | STARTED | Study Drug Ranexa Then Placebo | 10 | |
| Perod 2 | STARTED | Placebo Then Study Drug Ranexa | 10 | |
| Perod 2 | COMPLETED | Study Drug Ranexa Then Placebo | 10 | |
| Perod 2 | COMPLETED | Placebo Then Study Drug Ranexa | 10 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Study Drug | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Study Drug | 0 | 20 |
| Total, other adverse events | Placebo | 0 | 20 |
| Total, serious adverse events | Study Drug | 0 | 20 |
| Total, serious adverse events | Placebo | 0 | 20 |
Source ClinicalTrials.gov
Papers15
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Study Drug vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00570089
GET https://conductscience.org/api/trials/v1/NCT00570089/registered